David A. Siegel Rigel Pharmaceuticals Inc Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.12 - $1.57 $39,658 - $55,592	-35,409 Reduced 5.38%	623,191 $922,000
Q4 2023 Feb 14, 2024	SELL	$0.72 - $1.56 $268,337 - $581,397	-372,691 Reduced 36.14%	658,600 $954,000
Q3 2023 Nov 14, 2023	SELL	$1.07 - $1.39 $1.25 Million - $1.62 Million	-1,164,400 Reduced 53.03%	1,031,291 $1.11 Million
Q2 2023 Aug 14, 2023	SELL	$1.12 - $1.82 $191,520 - $311,220	-171,000 Reduced 7.23%	2,195,691 $2.83 Million
Q1 2023 May 15, 2023	BUY	$1.25 - $2.0 $709,625 - $1.14 Million	567,700 Added 31.56%	2,366,691 $3.12 Million
Q4 2022 Feb 14, 2023	SELL	$0.67 - $11.9 $100,031 - $1.78 Million	-149,300 Reduced 7.66%	1,798,991 $2.7 Million
Q3 2022 Nov 14, 2022	BUY	$1.1 - $12.2 $1.8 Million - $19.9 Million	1,632,700 Added 517.35%	1,948,291 $2.3 Million
Q2 2022 Aug 15, 2022	BUY	$0.67 - $3.19 $176,746 - $841,522	263,800 Added 509.35%	315,591 $357,000
Q1 2022 May 16, 2022	SELL	$2.22 - $3.45 $1.14 Million - $1.78 Million	-514,800 Reduced 90.86%	51,791 $155,000
Q4 2021 Feb 14, 2022	SELL	$2.36 - $3.57 $2.95 Million - $4.46 Million	-1,248,100 Reduced 68.78%	566,591 $1.5 Million
Q3 2021 Nov 15, 2021	SELL	$3.5 - $4.5 $332,500 - $427,500	-95,000 Reduced 4.97%	1,814,691 $6.59 Million
Q2 2021 Aug 16, 2021	SELL	$3.09 - $4.54 $1.42 Million - $2.09 Million	-459,800 Reduced 19.41%	1,909,691 $8.29 Million
Q1 2021 May 17, 2021	BUY	$3.35 - $4.93 $6.73 Million - $9.91 Million	2,010,000 Added 559.12%	2,369,491 $8.1 Million
Q4 2020 Feb 16, 2021	SELL	$2.35 - $3.74 $1.59 Million - $2.53 Million	-675,500 Reduced 65.27%	359,491 $1.26 Million
Q3 2020 Nov 16, 2020	BUY	$1.78 - $4.13 $318,798 - $739,683	179,100 Added 20.93%	1,034,991 $2.48 Million
Q2 2020 Aug 14, 2020	BUY	$1.41 - $2.05 $66,552 - $96,759	47,200 Added 5.84%	855,891 $1.57 Million
Q1 2020 May 15, 2020	BUY	$1.27 - $3.0 $28,194 - $66,600	22,200 Added 2.82%	808,691 $1.26 Million
Q4 2019 Feb 14, 2020	BUY	$1.6 - $2.43 $189,280 - $287,469	118,300 Added 17.7%	786,491 $1.68 Million
Q3 2019 Nov 14, 2019	BUY	$1.63 - $2.62 $172,454 - $277,196	105,800 Added 18.81%	668,191 $1.25 Million
Q2 2019 Aug 14, 2019	BUY	$2.02 - $2.61 $101,000 - $130,500	50,000 Added 9.76%	562,391 $1.47 Million
Q1 2019 May 15, 2019	BUY	$2.0 - $2.65 $678,800 - $899,410	339,400 Added 196.2%	512,391 $1.32 Million
Q4 2018 Feb 14, 2019	SELL	$2.08 - $3.36 $74,880 - $120,960	-36,000 Reduced 17.23%	172,991 $398,000
Q3 2018 Nov 14, 2018	BUY	$2.6 - $3.59 $132,340 - $182,731	50,900 Added 32.2%	208,991 $671,000
Q2 2018 Aug 14, 2018	BUY	$2.83 - $4.11 $30,847 - $44,799	10,900 Added 7.41%	158,091 $447,000
Q1 2018 May 15, 2018	BUY	$3.54 - $4.54 $157,176 - $201,576	44,400 Added 43.19%	147,191 $521,000
Q4 2017 Feb 14, 2018	BUY	$3.23 - $4.3 $77,520 - $103,200	24,000 Added 30.46%	102,791 $399,000
Q3 2017 Nov 14, 2017	BUY	$2.18 - $2.57 $171,764 - $202,492	78,791	78,791 $200,000

Others Institutions Holding RIGL

# of Institutions

Shares Held

334K

Call Options Held

Put Options Held

View Full List

About RIGEL PHARMACEUTICALS INC

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.96B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

More about RIGL

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account